{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T04:16:32Z","timestamp":1682828192270},"reference-count":25,"publisher":"Japan Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1507\/endocrj.ej22-0520","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T22:10:02Z","timestamp":1672179002000},"page":"419-426","source":"Crossref","is-referenced-by-count":0,"title":["Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report"],"prefix":"10.1507","volume":"70","author":[{"given":"Norikazu","family":"Toi","sequence":"first","affiliation":[{"name":"Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Imanishi","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Kurajoh","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Morioka","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Shinto","sequence":"additional","affiliation":[{"name":"Shinto Orthopedics and Rheumatology Clinic, Osaka 545-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, et al. (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429\u2013435.","DOI":"10.1359\/JBMR.0301264"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Crotti C, Bartoli F, Coletto LA, Manara M, Marini E, et al. (2021) Tumor induced osteomalacia: a single center experience on 17 patients. Bone 152: 116077.","DOI":"10.1016\/j.bone.2021.116077"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, et al. (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3: 17044.","DOI":"10.1038\/nrdp.2017.44"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18: R53\u2013R77.","DOI":"10.1530\/ERC-11-0006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia. Bone Rep 7: 90\u201397.","DOI":"10.1016\/j.bonr.2017.09.002"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6 Imanishi Y, Shoji T, Emoto M (2022) Complications and treatments in adult X-linked hypophosphatemia. Endocrines 3: 560\u2013569.","DOI":"10.3390\/endocrines3030047"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Nagata Y, Imanishi Y, Ishii A, Kurajoh M, Motoyama K, et al. (2011) Evaluation of bone markers in hypophosphatemic rickets\/osteomalacia. Endocrine 40: 315\u2013317.","DOI":"10.1007\/s12020-011-9512-z"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500\u20136505.","DOI":"10.1073\/pnas.101545198"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets\/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82: 674\u2013681.","DOI":"10.1210\/jcem.82.2.3765"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Imanishi Y, Ito N, Rhee Y, Takeuchi Y, Shin CS, et al. (2021) Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36: 262\u2013270.","DOI":"10.1002\/jbmr.4184"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Jan de Beur SM, Miller PD, Weber TJ, Peacock M, Insogna K, et al. (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36: 627\u2013635.","DOI":"10.1002\/jbmr.4233"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Miyaoka D, Imanishi Y, Yano M, Toi N, Nagata Y, et al. (2020) Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: case report. Bone Rep 13: 100736.","DOI":"10.1016\/j.bonr.2020.100736"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13 Day AL, Gutierrez OM, Guthrie BL, Saag KG (2020) Burosumab in tumor-induced osteomalacia: a case report. Joint Bone Spine 87: 81\u201383.","DOI":"10.1016\/j.jbspin.2019.07.012"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Oe Y, Kameda H, Nomoto H, Sakamoto K, Soyama T, et al. (2021) Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: a case report. Medicine (Baltimore) 100: e27895.","DOI":"10.1097\/MD.0000000000027895"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266\u2013281.","DOI":"10.1056\/NEJMra070553"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16 Hay JE (1995) Bone disease in cholestatic liver disease. Gastroenterology 108: 276\u2013283.","DOI":"10.1016\/0016-5085(95)90033-0"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, et al. (2008) Primary biliary cirrhosis and osteoporosis: a case-control study. J Bone Miner Metab 26: 379\u2013384.","DOI":"10.1007\/s00774-007-0833-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M (1996) Transcriptional control of osteoblast growth and differentiation. Physiol Rev 76: 593\u2013629.","DOI":"10.1152\/physrev.1996.76.2.593"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, et al. (1997) Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 12: 1502\u20131511.","DOI":"10.1359\/jbmr.1997.12.9.1502"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Colangelo L, Pepe J, Nieddu L, Sonato C, Scillitani A, et al. (2020) Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia. Osteoporos Int 31: 1383\u20131387.","DOI":"10.1007\/s00198-020-05369-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Colazo JM, Thompson RC, Covington NV, Dahir KM (2020) An intracranial mass causing tumor-induced osteomalacia (TIO): rapid and complete resolution of severe osteoporosis after surgical resection. Radiol Case Rep 15: 492\u2013497.","DOI":"10.1016\/j.radcr.2020.01.039"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Piemonte S, Romagnoli E, Cipriani C, De Lucia F, Pilotto R, et al. (2014) Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. Eur J Endocrinol 170: K1\u2013K4.","DOI":"10.1530\/EJE-13-0581"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Dadoniene J, Miglinas M, Miltiniene D, Vajauskas D, Seinin D, et al. (2016) Tumour-induced osteomalacia: a literature review and a case report. World J Surg Oncol 14: 4.","DOI":"10.1186\/s12957-015-0763-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Saeki C, Saito M, Oikawa T, Nakano M, Torisu Y, et al. (2020) Effects of denosumab treatment in chronic liver disease patients with osteoporosis. World J Gastroenterol 26: 4960\u20134971.","DOI":"10.3748\/wjg.v26.i33.4960"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Kapila N, Gonzalez A, Rosado JM, Flocco G, Salomon F, et al. (2021) Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study. Therap Adv Gastroenterol 14: 17562848211037094.","DOI":"10.1177\/17562848211037094"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/4\/70_EJ22-0520\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T04:08:36Z","timestamp":1682741316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/4\/70_EJ22-0520\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej22-0520","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"EJ22-0520"}}